BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv7.26.0//EN
X-ORIGINAL-URL:https://steven-kantor.com/
X-WR-CALNAME:Steven A Kantor
X-WR-CALDESC:
X-WR-TIMEZONE:America/New_York
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T030000
RRULE:FREQ=YEARLY;BYMONTH=03;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T010000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-a1c3ae6c49a89d92aef2d423dadb477f@steven-kantor.com
DTSTART;TZID=America/New_York:20260617T080000
DTEND;TZID=America/New_York:20260617T180000
DTSTAMP:20260617T080024Z
CREATED:20260617
LAST-MODIFIED:20260616
PRIORITY:5
SEQUENCE:2
TRANSP:OPAQUE
SUMMARY:Life Sciences Collaborative – NJ Meeting Highlights Innovation in mRNA Therapeutics and Cancer Treatment
DESCRIPTION:The Life Sciences Collaborative – New Jersey Chapter held its June 11 monthly meeting at Princeton Innovation Center BioLabs in Princeton, New Jersey, bringing together life sciences executives, investors, entrepreneurs, and industry leaders for a discussion on emerging biotechnology innovations and the future of healthcare.\nFeatured speakers included Eric Ekland, President and CEO of Anvesana, and Raghu Rao, Interim CEO of Guidant BioTherapeutics.\nAdvancing mRNA Therapies for Rare Blood Disorders\nEric Ekland provided an update on Anvesana, an early-stage biotechnology company focused on developing mRNA-based therapeutics for rare inherited blood and bleeding disorders, including hemophilia.\nBacked by the Pathway to Cures Foundation, Anvesana is working to leverage advances in mRNA technology to address significant unmet medical needs. While the company maintains a strong presence in New York City, its scientific leadership and regional connections continue to strengthen ties to the growing New Jersey life sciences ecosystem.\nNext-Generation Oncology Innovation\nRaghu Rao discussed the progress being made at Guidant BioTherapeutics, a clinical-stage biotechnology company headquartered in the Princeton area.\nGuidant is focused on developing next-generation oncology therapies through its proprietary Navigated Delivery™ platform, which supports the development of dual-cytokine therapies and antibody-drug conjugates (ADCs) designed to improve cancer treatment outcomes.\nThe presentation provided valuable insight into the opportunities and challenges associated with advancing innovative oncology products through clinical development.\nBuilding the Future of Biotechnology in New Jersey\nBeyond the science, the discussion focused on issues that impact many emerging biotechnology companies, including fundraising, clinical development, commercialization strategies, and building sustainable organizations capable of bringing breakthrough therapies to market.\nMeetings like these continue to highlight the strength of the New Jersey life sciences ecosystem and the important role innovative companies play in advancing healthcare and improving patient outcomes.\nThe Life Sciences Collaborative remains committed to bringing together founders, executives, investors, and industry leaders to share knowledge, build relationships, and support innovation throughout the life sciences industry.\n
URL:https://steven-kantor.com/events/life-sciences-collaborative-nj-meeting-highlights-innovation-in-mrna-therapeutics-and-cancer-treatment/
CATEGORIES:LSC - New Jersey
ATTACH;FMTTYPE=image/png:https://steven-kantor.com/wp-content/uploads/2026/06/ChatGPT-Image-Jun-16-2026-11_46_33-AM-e1781625709391.png
END:VEVENT
END:VCALENDAR